Evogene shareholders approve four 2026 proposals
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Evogene Ltd. (EVGN) reports that it held its annual general meeting of shareholders on September 4, 2026, with a quorum present and shareholder voting conducted on proposals previously described in its July 31, 2026 proxy materials. Proposals 1(a) and 2–4 were approved by the requisite shareholder vote.
Effective at the end of the meeting, Evogene’s board of directors consists of Nir Nimrodi, Adrian Percy, Leon Y. Recanati, Dan Falk, Yael Margolin, Yoshinori Oikawa, and Ofer Haviv, who also serves as CEO and President. The information in this report is incorporated by reference into Evogene’s existing Form F-3 and Form S-8 registration statements.
Key Figures
Key Terms
Report of Foreign Private Issuer regulatory
Form 20-F regulatory
Form F-3 regulatory
Form S-8 regulatory
registration statements regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Evogene Ltd. (EVGN) announce in its September 2026 Form 6-K?
Who are the current board members of Evogene Ltd. (EVGN) after the 2026 AGM?
Did Evogene (EVGN) confirm quorum at the September 4, 2026 annual general meeting?
How does this Evogene Ltd. (EVGN) 6-K affect its existing registration statements?
Where was Evogene Ltd. (EVGN)’s 2026 annual general meeting held?
AI-generated analysis. How Rhea-AI works. Not financial advice.